Inegy

Simvastatin/Ezetimibe, the active ingredient in Inegy, is a HMG‑CoA reductase inhibitor / cholesterol absorption inhibitor presented as an oral tablet for oral use. It treats hypercholesterolemia and mixed dyslipidemia in adult patients. GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy is used to manage lipid disorders and reduce cardiovascular risk associated with elevated cholesterol levels. - Hypercholesterolemia: lowers low‑density lipoprotein cholesterol (LDL‑C) to target levels. - Mixed dyslipidemia: reduces LDL‑C and triglycerides while modestly raising high‑density lipoprotein cholesterol (HDL‑C). - Primary prevention of cardiovascular disease: helps patients at risk achieve guideline‑recommended lipid goals.

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhoea. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: transient increase in ALT/AST. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Acute liver injury: marked elevation of hepatic enzymes or jaundice. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Myopathy: muscle weakness with elevated creatine kinase. - Pancreatitis: abdominal pain with elevated pancreatic enzymes.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Liver function monitoring: obtain baseline ALT/AST and repeat periodically. - Muscle symptom assessment: educate patients to report unexplained muscle pain or weakness. - Concomitant medication review: avoid strong CYP3A4 inhibitors and certain fibrates. - Active liver disease: contraindicated in patients with ongoing hepatic impairment. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Inegy can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may increase simvastatin exposure. - Gemfibrozil or high‑dose fenofibrate: heightened risk of myopathy. - Niacin (high dose): additive muscle toxicity. - Cyclosporine: increases both components' plasma concentrations. - Certain HIV protease inhibitors: elevate simvastatin levels.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in anticoagulant effect. - Digoxin: may require serum level monitoring. - Antacids containing aluminum or magnesium: can reduce ezetimibe absorption. - Grapefruit juice: modest increase in simvastatin exposure. - Macrolide antibiotics (e.g., erythromycin): may modestly raise simvastatin levels.